Trial intelligence / Profile preview

Effect of Low-dose Interferon alfa-2a on post-operative immune suppression in colon cancer surgery

2017-001566-21Phase 2Completed

Sponsor: Ismail GÃ¶genur
Start: Jun 2017
Modality: Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 2, randomised trial in colon cancer comparing Peginterferon alfa-2a with Placebo (2 arms). Primary endpoint: Genetic transcription of immunologically relevant genes. Started Jun 2017; status: completed.

Drugs

peginterferon alfa-2a

Conditions

colon cancer

Beyond the preview

Go deeper on 2017-001566-21.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2017-001566-21.